HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 12, December 2017 – Skin diseases and allergic reactions       » Gigantic DNA database to be built in Nanjing       » Ineffective baby vaccines by two companies recalled       » Head transplant 'never' to be allowed       » Asia-Pacific, the rising region for cancer vaccine clinical trials       » The hard truth about Eczema      
EYE ON CHINA
Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
Epigenomics AG, a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd., a leading Chinese clinical diagnostics company, have entered into a licensing and supply agreement for Epigenomics' Epi proLung® tissue assay for the Chinese market.

Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.

Noel Doheny, CEO of Epigenomics' US subsidiary, commented: "We are excited to enter into this agreement regarding our Epi proLung® tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung® in China. This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market."

"Epigenomics' Epi proLung® assay fills an unmet need in current lung cancer diagnosis," added Shiang Huang, M.D., CEO of Kindstar. "We are very pleased to add Epi proLung® to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market."

Click here for the complete issue.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases and Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy